MediWound wins $3.3 million US Department of War grant for room-temperature NexoBrid development

• MediWound received an additional USD 3.3 million award from the US Department of War for a room-temperature-stable NexoBrid formulation.
• Total program budget increased to USD 21.8 million, supporting development through an FDA IND submission for battlefield burn care.
• Project falls under Vericel’s North American license, which grants Vericel exclusive development, commercial rights to NexoBrid in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9831165) on September 22, 2026, and is solely responsible for the information contained therein.